Compass Therapeutics, Inc. · NASDAQ:CMPX
Compass Therapeutics — Investor Presentation (April 2026)
16 slides from Compass Therapeutics's investor presentation, Apr 27, 2026
Slide 1: Corporate Presentation
Corporate Presentation Nasdaq: CMPX April 27, 2026
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared by Compass Therapeutics, Inc . ("we," "us," "our," or the “Company”) . Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the informat
Slide 3: COMPANION-002: Executive Summary
Primary endpoint (previously reported) : significant improvement in ORR 17.1% vs. 5.3% BICR - assessed ORR (p=0.031) Key secondary endpoint : highly significant improvement in PFS 4.7 vs. 2.6 months median BICR - assessed PFS (HR=0.44, p<0.0001) Key secondary endpoint : OS analyses confounded by cro
Slide 4: Phase 2/3 U.S. BTC Study design
Paclitaxel 80 mg/m 2 Days 1, 8 and 15 of every 28 - day cycle Tovecimig 10mg/kg Days 1 and 15 Paclitaxel 80 mg/m 2 Days 1, 8 and 15 of every 28 - day cycle COMPANION - 002: Phase 2/3 U.S. BTC Study Registrational - intent study in patients who have received one prior line of therapy 4 Crossover perm
Slide 5: Baseline Demographics
Paclitaxel n=57 Tovecimig + Paclitaxel n=111 63.0 65.0 Median (years) Age 24 (42.1) 53 (47.7) Male Sex 33 (57.9) 58 (52.3) Female 10 (17.5) 17 (15.3) Asian Race 40 (70.2) 84 (75.7) White 6 (10.5) 4 (3.6) African American 1 (1.8) 6 (5.4) Unknown/Other 30 (52.6) 62 (55.9) Intrahepatic Primary Location
Slide 6: Significant Improvement in Primary Endpoint of ORR
6 Paclitaxel Tovecimig + Paclitaxel COMPANION - 002 Study (BTC) n=57 n=111 Intent - to - Treat Population 3 (5.3%) 19 (17.1%) Overall Response Rate (CR+PR) p=0.031 Two - Sided p - value 0 (0.0%) 1 (0.9%) Complete Response (CR) Best Overall Response RECIST v1.1 by blinded independent central review (
Slide 7: Tovecimig Significantly Improves PFS (BICR)
COMPANION - 002: Tovecimig Significantly Improves PFS (BICR) ITT Analysis: HR=0.44, p<0.0001, 4.7 vs. 2.6 months median PFS 7 Tovecimig + paclitaxel Paclitaxel alone Censored Tovecimig + paclitaxel Paclitaxel alone Data cutoff from COMPANION - 002 as of April 2026.
Slide 8: OS Analysis Confounded by Crossover
COMPANION - 002: OS Analysis Confounded by Crossover Tovecimig + paclitaxel Paclitaxel alone Tovecimig + paclitaxel Control arm Censored 8 Data cutoff from COMPANION - 002 as of April 2026. ITT analysis: HR=1.05, p=0.78, 8.9 vs. 9.4 months median OS Control arm includes 31 patients (54%) who crossed
Slide 9: Phase 2/3 Efficacy Results
9 Phase 2/3 COMPANION - 002: Efficacy Results Hazard Ratio Two - Sided p - value Paclitaxel (n=57) Tovecimig + Paclitaxel (n=111) Endpoint Primary Endpoint – p=0.031 3 (5.3%) 19 (17.1%) Overall Response Rate Key Secondary Endpoints (months) 0.44 p<0.0001 2.6 4.7 Progression Free Survival 1.13 p=0.65
Slide 10: PFS2: Tovecimig Significantly Improves PFS Post-Crossover
PFS2: Tovecimig Significantly Improves PFS Post - Crossover 10 Prespecified secondary analysis (n=31): HR=0.36, p=0.0016, 3.5 vs. 1.9 months median PFS Data cutoff from COMPANION - 002 as of April 2026.
Slide 11: Tovecimig Significantly Improved OS in Crossover Patients
Tovecimig Significantly Improved OS in Crossover Patients 11 Post hoc subset analysis (n=31 vs. n=26): HR=0.54, p=0.04, 12.8 vs. 6.1 months median OS Data cutoff from COMPANION - 002 as of April 2026.
Slide 12: Crossover Patients Progressed Faster on Paclitaxel Monotherapy
Crossover Patients Progressed Faster on Paclitaxel Monotherapy 12 Post hoc subset analysis (n=31 vs. n=26): 1.9 vs. 3.6 months median PFS, p=0.007 Data cutoff from COMPANION - 002 as of April 2026.
Slide 13: Adverse Events
Paclitaxel n=53 Tovecimig + Paclitaxel n=108 Related ≥ Grade 3 ≥ Grade 3 Related Overall Related ≥ Grade 3 ≥ Grade 3 Related Overall 2 (4) 3 (6) 23 (43) 24 (45) 12 (11) 16 (15) 66 (61) 72 (67) Fatigue 1 (2) 3 (6) 2 (4) 10 (19) 48 (44) 56 (52) 65 (60) 75 (69) Hypertension 14 (26) 14 (26) 20 (38) 20 (
Slide 14: Study Summary and Next Steps
COMPANION - 002: Study Summary and Next Steps Results Endpoint / Analysis • Significant improvement : 17.1% vs 5.3% BICR - assessed ORR (p=0.031) Primary ORR • Significant improvement : 4.7 vs 2.6 months median PFS (HR=0.44, p<0.0001) Key Secondary PFS • OS was not met : 8.9 vs 9.4 months median OS
Slide 15: Tovecimig: Potential to Become Standard of Care in 2L BTC
Tovecimig : Potential to Become Standard of Care in 2L BTC 15 1. PMID: 34303267 ORR N Program Analysis 17.1% (p=0.031) 111 Combo Tovecimig + Paclitaxel ITT 5.3% 57 Control 31 Crossover Patients Initially Randomized to Paclitaxel Subset 26 Paclitaxel Median Progression Free Survival Months 0 2 4 6 8
Slide 16: Compass Therapeutics website
Website: compasstherapeutics.com Nasdaq: CMPX Compass Therapeutics
Compass Therapeutics — Investor Presentation (April 2026) on 6ix